Citadel Advisors
DTIL icon

Citadel Advisors’s Precision BioSciences DTIL Stock Holding History

Citadel Advisors’s Portfolio DTIL Stock Details DTIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$638K Buy
115,952
+100,204
+636% +$462K ﹤0.01% 8703
2025
Q4 		$65.5K Sell
15,748
-6,394
-29% -$36.3K ﹤0.01% 11901
2025
Q3 		$122K Buy
+22,142
New +$106K ﹤0.01% 11694
2025
Q1 		– Sell
-153,675
Closed -$586K – 14682
2024
Q4 		$586K Buy
153,675
+56,400
+58% +$412K ﹤0.01% 8212
2024
Q3 		$872K Hold
97,275
– – ﹤0.01% 7138
2024
Q2 		$946K Hold
97,275
– – ﹤0.01% 6691
2024
Q1 		$1.32M Sell
97,275
-18,250
-16% -$223K ﹤0.01% 6362
2023
Q4 		$1.27M Buy
115,525
+11,061
+11% +$119K ﹤0.01% 6225
2023
Q3 		$1.07M Buy
104,464
+14,063
+16% +$216K ﹤0.01% 6429
2023
Q2 		$1.43M Sell
90,401
-4,179
-4% -$95.5K ﹤0.01% 5768
2023
Q1 		$2.14M Buy
94,580
+28,879
+44% +$952K ﹤0.01% 5226
2022
Q4 		$2.35M Buy
65,701
+7,217
+12% +$285K ﹤0.01% 5182
2022
Q3 		$2.28M Buy
58,484
+11,101
+23% +$527K ﹤0.01% 5337
2022
Q2 		$2.27M Buy
47,383
+34,198
+259% +$2.01M ﹤0.01% 5290
2022
Q1 		$1.22M Buy
13,185
+11,480
+673% +$1.56M ﹤0.01% 7253
2021
Q4 		$379K Sell
1,705
-4,943
-74% -$1.38M ﹤0.01% 10361
2021
Q3 		$2.3M Buy
6,648
+3,560
+115% +$1.21M ﹤0.01% 5997
2021
Q2 		$1.16M Sell
3,088
-4,556
-60% -$1.37M ﹤0.01% 7965
2021
Q1 		$2.37M Sell
7,644
-42,582
-85% -$14.9M ﹤0.01% 5996
2020
Q4 		$12.6M Buy
50,226
+48,200
+2,379% +$11.8M ﹤0.01% 2348
2020
Q3 		$374K Buy
2,026
+364
+22% +$72.4K ﹤0.01% 7766
2020
Q2 		$415K Sell
1,662
-3,558
-68% -$779K ﹤0.01% 7397
2020
Q1 		$945K Sell
5,220
-2,626
-33% -$687K ﹤0.01% 5437
2019
Q4 		$3.27M Buy
7,846
+6,785
+639% +$2.13M ﹤0.01% 3660
2019
Q3 		$267K Sell
1,061
-1,269
-54% -$413K ﹤0.01% 7735
2019
Q2 		$926K Buy
2,330
+720
+45% +$290K ﹤0.01% 5807
2019
Q1 		$867K Buy
+1,610
New +$855K ﹤0.01% 5840

Other funds holding DTIL

OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Citadel Advisors's DTIL Position: Q1 2026 in Review

Citadel Advisors increased its Precision BioSciences (DTIL) stake by 636% in Q1 2026, buying an estimated $462K and bringing the position to 115,952 shares worth $638K. The position accounts for ﹤0.01% of the portfolio, ranked #8703.

Citadel Advisors first reported a position in DTIL in Q1 2019 and has held it in 27 quarters since. The position peaked at $12.6M in Q4 2020. 78 funds tracked by Wall St. Rank hold DTIL as of Q1 2026.

  • Citadel Advisors held 115,952 shares of Precision BioSciences worth $638K as of Q1 2026.
  • Citadel Advisors bought 100,204 Precision BioSciences shares in Q1 2026, an estimated $462K.
  • Precision BioSciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #8703 holding.
  • Citadel Advisors first reported a position in Precision BioSciences in Q1 2019 and has held it in 27 quarters since.
  • Citadel Advisors's Precision BioSciences position peaked at $12.6M in Q4 2020.
  • 78 funds tracked by Wall St. Rank held Precision BioSciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.